How to appeal a UnitedHealthcare spinal muscular atrophy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for spinal muscular atrophy

Cited policy: OptumRx / UHC Zolgensma (Onasemnogene Abeparvovec-xioi) PA — Gene Therapy

Pediatric patient <2 yr at administration. Bi-allelic SMN1 mutations confirmed (homozygous exon 7 deletion or compound heterozygous). SMN2 copy number documented. AAV9 IgG titer <=1:50 (ECLIA or ELISA). Baseline ALT/AST <2x ULN, troponin-I <ULN, platelets >=67,000. Prednisolone 1 mg/kg/d planned. Administered at COE. Single lifetime dose. Some plans cap at weight 21 kg.

How UnitedHealthcare denies spinal muscular atrophy — and how to counter it

Where UnitedHealthcare pushes back: 1) Patient over 2 yr or weight >21 kg; 2) AAV9 antibody titer concerns; 3) Combination with Spinraza/Evrysdi labeled experimental; 4) Insufficient SMN2 copy data.

Counter-arguments that hold up: FDA label is AGE <2 yr — weight is dosing parameter (combination kits required >=13.6 kg per label) NOT eligibility. STR1VE-US Lancet Neurol 2021 + SPR1NT Lancet Neurol 2022 (Strauss) approval datasets enrolled by age. Some payer 21-kg cap is plan-imposed, NOT FDA. AAV9 IgG titer threshold is <=1:50 per label — submit ECLIA report; if elevated, recheck 4-12 wk per Novartis FDA dosing guide. Combination/sequential post-Zolgensma + Spinraza/Evrysdi maintenance supported by RESTORE registry + Mercuri 2024 reviews + Cure SMA real-world data — different mechanisms (gene replacement vs SMN2 splicing). Cite NURTURE / SPR1NT / RAINBOWFISH for pre-symptomatic eligibility per Glascock 2018/2020 newborn-screening recommendations.

What UnitedHealthcare typically denies for spinal muscular atrophy

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Spinraza (nusinersen)
• Evrysdi (risdiplam)
• Zolgensma (onasemnogene)
• Combination/sequential
• Switching therapy
• BiPAP / NIV

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.